The White House withdrew Heidi Overton’s nomination to lead the FDA on November 17, 2026, one day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on advancing her to the full Senate. The decision followed bipartisan opposition, including from committee chair Sen. Bill Cassidy over Overton’s involvement in childhood vaccine policy changes and questions about her experience. Overton, a physician and White House domestic policy official nominated in August after serving at the America First Policy Institute, faced additional scrutiny on mifepristone access, vaping policy, and abortion-related positions during her September confirmation hearing. With Democrats set to control the Senate after January, the withdrawal leaves the agency under an acting commissioner and removes any near-term path to confirmation.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”. If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”. The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution. The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.